Sponsor Dossier
Ferring Pharmaceuticals
Sponsor Dossier for Ferring Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADIN
- Brand: CERVIDIL
- Brand: CORTIMENT
- Brand: DECAPEPTYL
- Brand: DURATOCIN
- Brand: ENDOMETRIN
- Brand: FIRMAGON
- Brand: GLYPRESSIN
- Device (sponsor): Rectal medication/infusion catheter
- Device (sponsor): Syringe, hypodermic, metered-delivery
- Device (sponsor): Euflexxa 1% sodium hyaluronate - Synovial fluid supplementation substance
About
Ferring Pharmaceuticals is an Australian Private Company with ABN 87003037170, registered in New South Wales and currently Active.
Portfolio
Ferring Pharmaceuticals has 15 brands on the ARTG, of which 14 are indexable and 14 carry a Product Information document. 7 brands are PBS-listed, 7 have a PBAC outcome on record, and 7 have an AusPAR on record. Notable brands include ADIN, CERVIDIL, CORTIMENT, DECAPEPTYL, DURATOCIN, ENDOMETRIN, FIRMAGON, GLYPRESSIN, MENOPUR, MINIRIN, NOCDURNA, OCTOSTIM.
Therapeutic focus
— Reproductive Health: 6 brands — Gastroenterology: 3 brands — Endocrinology: 2 brands — Oncology: 1 brand — Hepatology: 1 brand — Renal: 1 brand — Haematology: 1 brand
PBS footprint
7 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2022-07-01, across 7 brands with a PBAC outcome on record. The latest AusPAR is 2018-09-10, across 7 brands with an AusPAR on record.